Altre lingue Daiichi Sankyo Co., Ltd.

Azioni

4568

JP3475350009

Tempo differito Japan Exchange Altri mercati azionari 06:34:49 24/04/2024			Variaz. 5gg	Var. 1 gen.
4.687 ^JPY	+0,51%		+5,49%	+21,05%

19/04	Le tensioni in Medio Oriente danneggiano i mercati azionari asiatici	MT
10/04	Il test diagnostico di Roche per il cancro al seno metastatico a basso contenuto di HER2 ottiene il marchio CE	MT

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

Middle East Tensions Dent Asian Stock Markets	19/04
Roche’s HER2-Low Metastatic Breast Cancer Diagnostic Test Secures CE Mark	10/04
Roche erhält CE-Kennung für erstes Brustkrebs-Begleitdiagnostikum	10/04
Scholz setzt auf weitere Pharma-Investitionen in Deutschland	08/04
AstraZeneca's Enhertu Receives FDA Approval for HER2-Positive Solid Tumor Indication	08/04
Astrazeneca - Enhertu approved in the US as first tumour-agnostic HER2-directed therapy for previously treated patients with metastatic HER2-Positive solid tumours	08/04
AstraZeneca, Daiichi Sankyo Secure Accelerated US FDA Clearance for Cancer Treatment Enhertu	08/04
AstraZeneca : approbation étendue pour Enhertu aux USA	08/04
AstraZeneca hails neurological data for Ultomiris, Soliris	08/04
AstraZeneca, Daiichi Sankyo's Solid Tumor Drug Wins US FDA's Accelerated Approval	08/04
Astra hails neurology data; CVS flags cyberattack	08/04
AstraZeneca's, Daiichi's Enhertu receives US FDA approval	08/04
Les valeurs à suivre à Paris et en Europe (actualisé)	08/04
AstraZeneca Wins US Approval for Solid Tumor Treatment	07/04
Daiichi Sankyo : ENHERTU® Approved in the U.S. as First Tumor Agnostic HER2 Directed Therapy for Previously Treated Patients with Metastatic HER2 Positive Solid Tumors (375.5KB	06/04
Astrazeneca and Daiichi Sankyo's ENHERTU Receives Approval in US as First Tumor-Agnostic HER2-Directed Therapy for Previously Treated Patients with Metastatic HER2-Positive Solid Tumors	06/04
US FDA approves Daiichi, AstraZeneca drug for treatment of solid tumors	05/04
Un séisme de magnitude 6,0 secoue le nord-est du Japon, pas d'alerte au tsunami	04/04
Merck, Daiichi Sankyo Dose First Person in Phase 2/3 Trial of Raludotatug Deruxtecan to Treat Ovarian Cancer	03/04
Daiichi Sankyo - Datopotamab Deruxtecan Biologics License Application Accepted in the U.S. for Patients with Previously Treated Metastatic HR Positive, HER2 Negative Breast Cancer	03/04

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Daiichi Sankyo Co., Ltd.

Azioni

4568

JP3475350009

Altre lingue

Filtri